Help
Options
Didn't know it?
click below
click below
Knew it?
click below
click below
Don't Know
Remaining cards (0)
Know
retry
shuffle
restart
0:00
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.
Normal Size Small Size show me how
Normal Size Small Size show me how
Bipolar Pharma
Behavioral Medicine Pharmacology
| Question | Answer |
|---|---|
| Bipolar: theories | monoamine,dysregulation, anticholinergic, kindling, neuroendocrine, membrane & cation hypothesis, secondary messenger system, biologic rhythms, switch phenomenon |
| Lithium MOA | not well known; Block DA rec sensitivity; inc NE release in depn; dec NE release in mania; reduces beta-adrenergic stim of adenylate cyclase; inc 5-HT synth |
| Lithium indicated for | acute mania; maintenance |
| Lithium advantages | antidep & antimanic fx (no switching nec); prevent relapse; better than valproate at prevent suicide |
| Lithium: best results in pts: | Fewer prior episodes; hx euthymia; Periods of good functioning; Pos FH w/Lithium |
| Lithium: reduced fx: | severe mania w/psychotic; mixed episodes; rapid / continuous cycling; etoh/ drug abuse |
| Lithium dosing | start at 600-900; inc by 300 q 2-3d (target 900-2400) |
| Lithium Monitoring | Draw trough 12h post last dose (tx day 5); then 1-2 wks for 1st mos; 5 days post dose change |
| Lithium tx serum level | 0.8 to 1.2 mEq/L (acute manic: poss 1.2 – 1.5); SR has no ref range |
| Lithium half life | usu 24 h (8 – 20 h in mania) |
| Lithium AE (early) | Blocks ADH fx on its receptors (polydipsia / polyuria); mx weakness; fine hand (intentional) tremor |
| Lithium AE (late) | NDI; increased lytes (Na, K, H2O), Cr; cardiac; persistent neuro probs (memory loss; MG, EPS); thyroid; GI; inc WBC & wt |
| Leading cause of lithium noncompliance | loss of creativity / memory |
| Lithium toxicity factors | Na restriction; dehydration; drug interactions |
| Lithium: mild toxicity = | 1.5 – 2.0; prob memory/conc; GI; tremor |
| Lithium: moderate toxicity = | 2.0-2.5; confusion, ataxia, nystagmus, inc DTR |
| Lithium: severe toxicity = | over 3.0; Choreoathetosis, seizure, coma, death |
| Tx lithium tox (>2.5) | d/c lithium; gastric lavage; monitor levels |
| Tx lithium tox (>3.5) | d/c d/c lithium; hemodialysis; monitor levels |
| Lithium CI | Renal dz; severe CV dz; hx leukemia; first tri of PG; hypersensitivity; breastfeeding? |
| Drugs that have anti-kindling properties | anticonvulsants (Valpro, carbamazepine, lamotrigine) |
| Bipolar drugs: category D (avoid in PG, dc in first trimester): | lithium, valpro, carba |
| Valpro MOA | Unk; prob inhib GABA metab &stim GABA synth |
| Valpro good for: | FDA: acute mania, rapid cycling (> lithium at mixed, secondary bipolar, subst induced) |
| Valpro less good for: | depression |
| Valpro absorption delayed: | with food |
| Valpro AE | GI, sedation, ataxia/tremor, low plt, liver probs |
| Carbamazepine MOA | Unk; prob block voltage-sensitive Na+ channels; Block CA+ influx thru NMDA-glutamate receptor |
| Carbamazepine efficacy | XR same as lithium; also acute mania, prophylaxis, bipolar depn |
| Carbamazepine better than lithium: | Severe mania; Rapid cycling; Mixed episodes |
| Carbamazepine dosing | start 200-400 mg/d; target 400-2400; max 15mg/kg/d |
| Carbamazepine monitoring | no est tx level; anticonvulsant = 6-12 mcg/ml; carba levels 12h postdose & day 6 |
| Carbamazepine PK | well absorbed (not affected by food); peak levels in 1-5 hr; 80% pro bound |
| Carbamazepine AE | CNS tox; GI (divide doses); leukopenia, hepatotox, low plt; SIADH, osteomalacia, derm |
| Carbamazepine potentially lethal: | >15 mcg/ml |
| Carbamazepine CI | bone marrow depn; hypersensitivity |
| Lamotrigine MOA | Blocks voltage-sensitive Na+ and Ca+ channels |
| Lamotrigine efficacy | maintenance (esp bipolar depn); NOT for acute mania |
| Lamotrigine PK | well absorbed (not affected by food); peak levels 1-4 hr; half life 25 hr (so x1/d dose) (inc to 60 hr w/valpro) |
| Lamotrigine AE | usu well tolerated; Stevens Johnsons syndrome; rash |
| antipsychotics dosing | Risperidone, olanzapine, quetiapine: mono or combo w/valp or lithium; aripiprazole, ziprasidone: monotx |
| antipsychotics good for: | acute mania; mixed (Quetiapine: bipolar depn) |
| SSRIs in bipolar depn | monotx inappropriate; high uncertainty in risk to manic switch |
| Benzo: benefit in bipolar | Reduce insomnia and agitation in acute mania |
| CCBs: benefit in bipolar | in lithium pts unable to tolerate AE |
Created by:
Abarnard
Popular Pharmacology sets